Stacy Enxing Seng
Stacy currently serves as a Venture Partner with Lightstone Ventures as well as an Independent Director for both public and venture-backed private companies. Prior to Venture/Independent Director work, Stacy spent the last 25 years in medtech, most recently serving as the President of Covidien¹s $1.7B Vascular business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medtech success that Stacy co-created in 2000 with ev3¹s founding team. Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement.
Stacy currently serves as a non-executive Independent Director for Hill-Rom Holdings, Inc., (NYSE: HRC), Sonova Holding AG (VTX: SOON), and private Spirox, Inc. and Solace Therapeutics. Past Director appointments include FIRE 1 and CVI.
Stacy holds a B.A. Public Policy, Michigan State University and an M.B.A. Harvard University.